Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MERCK, SHARP & DOHME CORP. et al v. CIPLA USA, INC. et al
Case Number:
1:13-cv-04017
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 19, 2014
Merck, BMS Circling Deal With Cipla Over Sustiva Generic
Merck Sharp & Dohme Corp. and Bristol-Myers Squibb Co. may be nearing the end of a patent row with Cipla USA Inc. over Cipla's plans to make a generic version of the antiretroviral drug Sustiva, according to a letter filed on Thursday in New Jersey federal court.
-
June 28, 2013
Merck, BMS Target Cipla USA Over Generic HIV Drug Sustiva
Merck Sharp & Dohme Corp. and Bristol-Myers Squibb Co. brought patent infringement allegations in New Jersey federal court Thursday against Indian generics maker Cipla USA Inc. over the company's plans to make a generic version of the HIV treatment Sustiva.